This opportunity is no longer accepting applications.
grant PAR-21-122

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)

This grant offers funding for studies to evaluate the biological effects and effectiveness of potential treatments for neurological or neuromuscular disorders. The aim is to show that these treatments, which may include small molecules or biologics, are promising enough for further development. This grant is part of the IGNITE program, which helps early-stage projects advance to meet the requi…

This FOA provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS miss…

Funding Source

Agency: National Institutes of Health
Program: SBIR

Awards & funding

Award Ceiling: $499,000
Award Amount: $499,000

Dates

Opportunity Released: March 11, 2021
Open for Submission: March 11, 2021
Submission Deadline: October 21, 2024
Application Window Closes: October 21, 2024

Documents

Secure Grant Funding 10x Faster

Scout delivers AI-powered grant writing paired with experts that's faster, more affordable, and built to win.

Already have an account? Sign In

Trusted by 500+ Happy Customers

Get opportunities sent to your inbox

The latest grant news and insights from our experts.

Save this opportunity and explore more

Share Opportunity

Share this opportunity with others.
Anyone with this link can view the opportunity details.